All Articles

Ms Shockney discusses the importance of clinical trials and extends an invitation to apply to the AONN+ Clinical Trials Committee.

JONS talks to Ms Allison and Ms Melton about their experiences as navigators, the critical touch points they have with patients, and how coordinating care is executed at their institutions.

An Interview with Oncology Financial Navigator Clara Lambert of Cowell Family Cancer Center

The co-chairs of the AONN+ Clinical Trials Committee discuss the roles of navigators and researchers in clinical trials, barriers to clinical trials that navigators can mitigate, and helpful tips and talking points to consider when talking about clinical trials with patients.

Although chimeric antigen receptor (CAR) T-cell therapies directed against the CD19 protein garnered much attention at ASH 2017, CAR T cells targeting B-cell maturation antigen (BCMA), a protein expressed nearly universally on multiple myeloma cells, were found to be remarkably effective in patients with heavily pretreated multiple myeloma.

A retrospective analysis of a large commercial payer database has demonstrated a link between various treatment episodes of acute myeloid leukemia (AML) and substantial economic burden.

Using a regimen with brentuximab vedotin (Adcetris) added to doxorubicin, vinblastine, and dacarbazine (A+AVD) instead of the standard regimen with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline treatment for advanced Hodgkin lymphoma reduced the risk for disease progression, death, or the need for additional therapy by 23%, according to new data presented at ASH 2017.

Venetoclax (Venclexta) plus ri­tuximab (Rituxan) achieved superior progression-free survival (PFS) and overall survival (OS) compared with standard-of-care bendamustine (Treanda/Bendeka) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Sotatercept, an investigational activin receptor IIA ligand trap, when used alone or in combination with ruxolitinib (Jakafi), safely increases hemoglobin levels in patients with myeloproliferative neoplasm–associated myelofibrosis, according to data from a phase 2, investigator-initiated clinical trial.

Although there have been major advancements in the treatment of hematologic malignancies in recent years, according to Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, the number of agents approved in 2017 for acute myeloid leukemia (AML) was nothing short of “phenomenal.”